Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
6 search results for:

Dorzagliatin 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 08-06-2022 | ADA 2022 | News | Article

    First-in-class glucokinase activator dorzagliatin could help treat some GK-MODY patients

    Dorzagliatin treatment has increased insulin secretion and improved beta-cell function in patients with glucokinase maturity-onset diabetes of the young, also known as MODY2, in a small phase 1 trial.

    Author:
    Helen Albert
    Published in:
    ADA Scientific Sessions; New Orleans, Louisiana: 3–7 June 2022
  2. 13-05-2022 | Dorzagliatin | News | Article

    DAWN: Support for dorzagliatin–metformin combination therapy in type 2 diabetes

    People with type 2 diabetes who have suboptimal glycemic control on metformin alone may benefit from add-on treatment with the dual-acting glucokinase activator dorzagliatin, report the DAWN investigators.

    Author:
    Claire Barnard
    Published in:
    Nat Med 2022; doi:10.1038/s41591-022-01803-5
  3. 15-06-2020 | ADA 2020 | Conference coverage | Article

    SEED trial: Dorzagliatin shows potential for type 2 diabetes

    Findings from the SEED trial provide further evidence to suggest that the dual-acting glucokinase activator dorzagliatin improves glycemic control compared with placebo and has a favorable safety profile in people with type 2 diabetes.

    Author:
    Claire Barnard
    Published in:
    ADA Scientific Sessions; 12–16 June 2020
  4. 10-05-2018 | Dorzagliatin | Article
    Expert commentary

    Dorzagliatin: Another hurdle overcome, but the finishing line is far

    Editorial board member Sanjay Kalra's take on the promising phase II trial results for dorzagliatin.

    Author:
    Sanjay Kalra
  5. 04-05-2018 | Dorzagliatin | Article

    Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: A dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study

    Zhu D et al. Lancet Diabetes Endocrinol 2018; Advance online publication. doi: 10.1016/S2213-8587(18)30105-0

  6. 08-05-2018 | Dorzagliatin | News | Article

    Glucokinase activation could be back in play for type 2 diabetes

    Phase II study findings indicate that the dual-acting glucokinase activator dorzagliatin has a sustained effect on glucose levels in patients with type 2 diabetes, without the adverse events previously associated with the medication class.

    Published in:
    Lancet Diabetes Endocrinol 2018; Advance online publication
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.